Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Wavelength-Pharmaceuticals-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Shionogi Inc

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Shionogi Signs New Contract with StemRIM Toward Investigator-initiated Clinical Study Implementation of S-005151

              Contact the Supplier

              Lead Product(s): Redasemtide

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: S-005151

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: StemRIM

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 30, 2020

              Details:

              The companies have entered a licensing agreement for S-005151 [Generic name: Redasemtide] to conduct investigator-initiated clinical studies targeting new indications in the future.

              Heartseed

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement

              Contact the Supplier

              Lead Product(s): Allogeneic iPSC-derived cardiomyocytes

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Itochu Chemical Frontier

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 10, 2020

              Details:

              Through this partnership, Heartseed will leverage ICF’s global network of academia and research institutions to explore iPS-Cell and Cardiomyocyte-related business opportunities.

              PharmaCompass__DigitalAd